TMCI Share Price Performance
US$2.80
-4.79 (-63.11%)
76.7% undervalued intrinsic discount
US$12.00
Fair Value
Price US$2.80
AnalystHighTarget US$12.00
AnalystConsensusTarget US$5.47
AnalystLowTarget US$4.00
Fair ValueUS$12.00
Share Pricen/a
Treace Medical Concepts, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
TMCI Community Narratives
AN
Fair Value US$12 76.7% undervalued intrinsic discount
Aging Population And Obesity Will Transform Foot Surgery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$5.47 48.8% undervalued intrinsic discount
Minimally Invasive Bunion Solutions Will Broaden Market Penetration
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$4 30.0% undervalued intrinsic discount
Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure
Catalysts About Treace Medical Concepts Treace Medical Concepts develops and commercializes specialized surgical systems for bunion correction and related foot and ankle procedures. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$4
30.0% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
0.24% p.a.
Profit Margin
12.91%
Future PE
12.22x
Price in 2028
US$5.12
Minimally Invasive Bunion Solutions Will Broaden Market Penetration
Key Takeaways Broadening of product portfolio and positive clinical adoption positions Treace for increased market penetration and long-term revenue growth. Improved cost discipline and expanding salesforce support enhanced margins and international market opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$5.47
48.8% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
2.1% p.a.
Profit Margin
13.02%
Future PE
15.48x
Price in 2028
US$6.91
Aging Population And Obesity Will Transform Foot Surgery
Key Takeaways Accelerated adoption of new systems and a highly skilled sales force could drive rapid revenue and earnings growth beyond the market's expectations. Expanding clinical evidence, demographic trends, and upcoming international launches are set to broaden the patient base and improve pricing power and margin resilience.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$12
76.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.54% p.a.
Profit Margin
12.32%
Future PE
27.4x
Price in 2028
US$14.8
Trending Discussion
Recently Updated Narratives
AN
Elective Bunion Procedure Deferrals Will Pressure Margins Yet Long-Term Demand Will Ultimately Endure
Fair Value: US$4 30.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TMCI: Consistent Execution Efforts Will Support Minimally Invasive Market Expansion Ahead
Fair Value: US$5.47 48.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Obesity Will Transform Foot Surgery
Fair Value: US$12 76.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Treace Medical Concepts, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.79
- 79.87%
- -22.89%
- 62.0%
About TMCI
- Founded
- 2013
- Employees
- 477
- CEO
- WebsiteView website
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
